Table 2 Nuclear staining of enadenotucirev in patients with CRC (IT injection vs IV infusion)
Cohort | Patient | Total number of sections | Nuclear staining (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
0 | > 0 ≤ 20 | > 20 ≤ 40 | > 40 ≤ 60 | > 60 ≤ 80 | > 80 ≤ 100 | No tumor | |||
A (IT injection) | IT0201 | 42 | 0 | 31 | 8 | 3 | 0 | 0 | 0 |
IT0203 | 14 | 0 | 0 | 0 | 2 | 11 | 1 | 0 | |
IT0204 | 42 | 1 | 0 | 0 | 0 | 4 | 30 | 7 | |
IT0301 | 21 | 7 | 14 | 0 | 0 | 0 | 0 | 0 | |
IT0302 | 28 | 14 | 11 | 2 | 1 | 0 | 0 | 0 | |
Total, n (%) | 147 (100.0) | 22 (15.0) | 56 (38.1) | 10 (6.8) | 6 (4.1) | 15 (10.2) | 31 (21.1) | 7 (4.8) | |
B (IV infusion) | IV0101 | 49 | 0 | 38 | 8 | 3 | 0 | 0 | 0 |
IV0201a | 21 | 0 | 0 | 3 | 0 | 11 | 7 | 0 | |
IV0301 | 70 | 0 | 25 | 11 | 13 | 6 | 8 | 7 | |
IV0302b | 63 | 0 | 21 | 9 | 9 | 4 | 6 | 14 | |
IV0303 | 21 | 0 | 11 | 7 | 3 | 0 | 0 | 0 | |
Totalb, n (%) | 224 (100.0) | 0 (0.0) | 95 (42.4) | 38 (17.0) | 28 (12.5) | 21 (9.4) | 21 (9.4) | 21 (9.4) | |